Parnell Pharmaceuticals Holdings Operating Margin 2014-2018 | PARNF
Current and historical operating margin for Parnell Pharmaceuticals Holdings (PARNF) over the last 10 years. The current operating profit margin for Parnell Pharmaceuticals Holdings as of June 30, 2018 is 0.00%.
| Parnell Pharmaceuticals Holdings Operating Margin Historical Data |
| Date |
TTM Revenue |
TTM Operating Income |
Operating Margin |
| 2018-03-31 |
$0.01B |
$0.01B |
66.67% |
| 2016-12-31 |
$0.01B |
$0.01B |
100.00% |
| 2016-09-30 |
$0.01B |
$0.01B |
100.00% |
| 2015-12-31 |
$0.01B |
$0.01B |
100.00% |
| 2015-09-30 |
$0.01B |
$0.01B |
100.00% |
| 2015-06-30 |
$0.01B |
$0.01B |
100.00% |
| 2014-12-31 |
$0.00B |
$0.00B |
100.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.000B |
$0.000B |
|
Parnell Pharmaceuticals Holdings Ltd. is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing animal health solutions. It manufactures and markets cattle reproduction, cattle mastitis, anesthetics, laminitis treatment, and orthopedic treatment products. The Company operates in four segments: Companion Animal, Production Animal-Unites States, and Production Animal-rest of the world and Manufacturing Operations. ZYDAX (R), GLYDE (R) and TERGIVE (R) are Parnell's premium osteoarthritis product suite. Parnell Pharmaceuticals Holdings Ltd. is headquartered in Alexandria, Australia.
|
